{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:02:59Z","timestamp":1769151779551,"version":"3.49.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T00:00:00Z","timestamp":1650758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. We aimed to evaluate the feasibility of next-generation sequencing (NGS) testing of circulating cell-free tumor DNA (ctDNA) in patients with ACC, to characterize the genomic landscape of alterations, and to identify potential clinically actionable mutations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective analysis of genomic data from 120 patients with ACC who had ctDNA testing between 12\/2016 and 10\/2021 using Guardant360 (Guardant Health, CA) was performed. ctDNA NGS analysis interrogated single nucleotide variants, fusions, indels, and copy number amplifications of up to 83 genes. The frequency of genomic alterations, landscape of co-occurring mutations, and pathogenic\/likely pathogenic alterations with potential targeted therapies was identified. The prevalence of alterations identified in ctDNA was compared to those detected in tissue using a publicly available database (cBioPortal).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age of this cohort was 53 years (range 21-81), and 56% of patients were female. Ninety-six patients (80%) had \u22651 somatic alteration detected. TP53 (52%), EGFR (23%), CTNNB1 (18%), MET (18%), and ATM (14%) were found to be the most frequently altered genes in ACC samples. Pathogenic and\/or likely pathogenic mutations in therapeutically relevant genes were observed in 56 patients (47%) and included EGFR, BRAF, MET, CDKN2A, CDK4\/6, and ATM. The most frequent co-occurring mutations were EGFR + MET (9%), MET + CDK4 (7%), EGFR + CDK4 (7%), and BRAF + MET (7%). The frequencies of mutations detected in ctDNA were similar to those detected in tissue.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Utilizing blood-based NGS to characterize genomic alterations in advanced ACC is feasible in over 80% of patients. Almost half of the patients had actionable mutations with approved therapies in other cancers. This approach might inform the development of personalized treatment options or identify clinical trials available for this aggressive malignancy.<\/jats:p><\/jats:sec>","DOI":"10.1093\/oncolo\/oyac061","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T20:25:52Z","timestamp":1647548752000},"page":"462-468","source":"Crossref","is-referenced-by-count":13,"title":["Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6385-1329","authenticated-orcid":false,"given":"Bassel","family":"Nazha","sequence":"first","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA , USA"},{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony Z","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiba I","family":"Dada","sequence":"additional","affiliation":[{"name":"Guardant Health , Redwood City, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leylah M","family":"Drusbosky","sequence":"additional","affiliation":[{"name":"Guardant Health , Redwood City, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline T","family":"Brown","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA , USA"},{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Ravindranathan","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA , USA"},{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley C","family":"Carthon","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA , USA"},{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer","family":"Kucuk","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA , USA"},{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Goldman","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA , USA"},{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viraj A","family":"Master","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA , USA"},{"name":"Department of Urology, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Asim","family":"Bilen","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA , USA"},{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,4,24]]},"reference":[{"issue":"8","key":"2022060819292450500_CIT0001","doi-asserted-by":"crossref","first-page":"636","DOI":"10.14740\/jocmr3503w","article-title":"The characteristics and trends in adrenocortical carcinoma: a United States population based study.","volume":"10","author":"Sharma","year":"2018","journal-title":"J Clin Med Res"},{"issue":"1-2","key":"2022060819292450500_CIT0002","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mce.2013.10.028","article-title":"Genetics and epigenetics of adrenocortical tumors.","volume":"386","author":"Lerario","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"2022060819292450500_CIT0003","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.suc.2004.02.003","article-title":"Laparoscopic adrenalectomy for malignancy.","volume":"84","author":"Sturgeon","year":"2004","journal-title":"Surg Clin North Am"},{"key":"2022060819292450500_CIT0004","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2022060819292450500_CIT0005","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/jso.23112","article-title":"Adrenocortical carcinoma: past, present, and future.","volume":"106","author":"Lafemina","year":"2012","journal-title":"J Surg Oncol"},{"key":"2022060819292450500_CIT0006","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1210\/jc.2017-02591","article-title":"Mitotane monotherapy in patients with advanced adrenocortical carcinoma.","volume":"103","author":"Megerle","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2022060819292450500_CIT0007","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma.","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"2022060819292450500_CIT0008","doi-asserted-by":"crossref","first-page":"101434","DOI":"10.1016\/j.beem.2020.101434","article-title":"Next-generation therapies for adrenocortical carcinoma.","volume":"34","author":"Altieri","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2022060819292450500_CIT0009","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1172\/JCI131041","article-title":"Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.","volume":"130","author":"Beltran","year":"2020","journal-title":"J Clin Invest"},{"issue":"7","key":"2022060819292450500_CIT0010","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/cancers11070998","article-title":"BRAF mutation status in circulating tumor DNA from patients with metastatic colorectal cancer: extended mutation analysis from the AGEO RASANC study.","volume":"11","author":"Mas","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2022060819292450500_CIT0011","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1634\/theoncologist.2019-0558","article-title":"Blood-based next-generation sequencing analysis of appendiceal cancers.","volume":"25","author":"Shaib","year":"2020","journal-title":"Oncologist"},{"key":"2022060819292450500_CIT0012","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.18632\/oncotarget.27588","article-title":"Blood-based next-generation sequencing analysis of neuroendocrine neoplasms.","volume":"11","author":"Zakka","year":"2020","journal-title":"Oncotarget"},{"key":"2022060819292450500_CIT0013","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2017.76.0033","article-title":"Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer.","volume":"36","author":"Stover","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022060819292450500_CIT0014","doi-asserted-by":"crossref","first-page":"L13","DOI":"10.1530\/ERC-17-0467","article-title":"Detection and monitoring of circulating tumor DNA in adrenocortical carcinoma.","volume":"25","author":"Garinet","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"2022060819292450500_CIT0015","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1210\/jc.2017-00174","article-title":"Identification of mutations in cell-free circulating tumor DNA in adrenocortical carcinoma: a case series.","volume":"102","author":"Creemers","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2022060819292450500_CIT0016","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","article-title":"Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies.","volume":"24","author":"Odegaard","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2022060819292450500_CIT0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base.","volume":"1","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"2022060819292450500_CIT0018","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2022060819292450500_CIT0019","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"2022060819292450500_CIT0020","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma.","volume":"46","author":"Assi\u00e9","year":"2014","journal-title":"Nat Genet"},{"key":"2022060819292450500_CIT0021","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1210\/jc.2018-01348","article-title":"Targeted molecular analysis in adrenocortical carcinomas: a strategy toward improved personalized prognostication.","volume":"103","author":"Lippert","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2022060819292450500_CIT0022","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1210\/jc.2013-2165","article-title":"Molecular screening for a personalized treatment approach in advanced adrenocortical cancer.","volume":"98","author":"De Martino","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2022060819292450500_CIT0023","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma.","volume":"29","author":"Zheng","year":"2016","journal-title":"Cancer Cell"},{"key":"2022060819292450500_CIT0024","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/jclinpath-2014-202514","article-title":"Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.","volume":"67","author":"Ross","year":"2014","journal-title":"J Clin Pathol"},{"key":"2022060819292450500_CIT0025","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41574-019-0221-7","article-title":"Adrenocortical carcinoma\u2014towards genomics guided clinical care.","volume":"15","author":"Crona","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"2022060819292450500_CIT0026","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-11-2692","article-title":"Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer.","volume":"18","author":"Volante","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2022060819292450500_CIT0027","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1677\/ERC-08-0224","article-title":"Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.","volume":"16","author":"Ronchi","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"2022060819292450500_CIT0028","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1530\/ERC-17-0095","article-title":"Topoisomerase 2\u03b1 and thymidylate synthase expression in adrenocortical cancer.","volume":"24","author":"Roca","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"2022060819292450500_CIT0029","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1210\/clinem\/dgz318","article-title":"Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib.","volume":"105","author":"Kroiss","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2022060819292450500_CIT0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma.","volume":"38","author":"Raj","year":"2020","journal-title":"J Clin Oncol"},{"key":"2022060819292450500_CIT0031","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer.","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"2022060819292450500_CIT0032","doi-asserted-by":"crossref","first-page":"e000469","DOI":"10.1136\/jitc-2019-000469","article-title":"Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma.","volume":"8","author":"Landwehr","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"2022060819292450500_CIT0033","doi-asserted-by":"crossref","first-page":"e13517","DOI":"10.1097\/MD.0000000000013517","article-title":"Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden: Two case reports.","volume":"97","author":"Mota","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"2022060819292450500_CIT0034","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1210\/clinem\/dgz014","article-title":"Development of an adrenocortical cancer humanized mouse model to characterize anti-PD1 effects on tumor microenvironment.","volume":"105","author":"Lang","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2022060819292450500_CIT0035","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","article-title":"Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade.","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov"},{"key":"2022060819292450500_CIT0036","article-title":"Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy.","volume":"510","author":"Thompson","year":"2021","journal-title":"JCO Precis Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/6\/462\/43984326\/oyac061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/6\/462\/43984326\/oyac061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T14:00:28Z","timestamp":1726840828000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/6\/462\/6573342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,24]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,4,24]]},"published-print":{"date-parts":[[2022,6,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac061","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,4,24]]}}}